


 Cite this: *Sens. Diagn.*, 2024, 3, 1724

## An rGO-doped laser induced graphene electrochemical biosensor for highly sensitive exosome detection

 Xiaoshuang Chen,<sup>a</sup> Xiaohui Yan,<sup>a</sup> Jiaoyan Qiu,<sup>a</sup> Xue Zhang,<sup>a</sup> Yunhong Zhang,<sup>a</sup> Hongpeng Zhou,<sup>a</sup> Yujuan Zhao,<sup>a</sup> Lin Han <sup>ab</sup> and Yu Zhang <sup>\*ab</sup>

In this study, we developed a novel electrochemical sensing chip integrated with reduced graphene oxide (rGO) with laser-induced graphene (LIG) for the detection of exosomes associated with breast cancer biomarkers. Employing laser-induced technology, a three-dimensional porous graphene material is fabricated on the surface of a flexible polyimide film, which is subsequently combined with rGO through  $\pi$ - $\pi$  stacking. This integration facilitates the doping of two-dimensional and three-dimensional material (2D/3D) structures, significantly enhancing the conductivity of the electrode material. Additionally, this approach markedly improves the surface hydrophobicity and biomolecule affinity of LIG, optimizing the immobilization of specific antibodies for exosomes. Importantly, this experiment marks the first occasion of merging two-dimensional rGO with three-dimensional LIG, resulting in the construction of a high-performance biosensing chip that enables specific capture and highly sensitive detection of exosomes. Under optimized conditions, the quantitative detection range for exosomes is established at  $5 \times 10^2$  to  $5 \times 10^5$  particles per  $\mu\text{L}$ , with a limit of detection (LOD) of 166 particles per  $\mu\text{L}$ . The biosensor is successfully used to analyze exosomes in breast cancer cell lines and patient serum samples, proving its practical application. This electrochemical biosensing chip offers significant practical application value in the early screening and diagnosis of diseases.

 Received 31st May 2024,  
 Accepted 5th August 2024

DOI: 10.1039/d4sd00181h

[rsc.li/sensors](https://rsc.li/sensors)

## Introduction

Breast cancer stands as the most prevalent malignant tumor among women, representing a grave threat to their health and well-being. According to the latest forecasts on the global cancer burden released by the International Agency for Research on Cancer (IARC) in 2020,<sup>1</sup> breast cancer has emerged as the leading type of malignant tumor worldwide, constituting 11.7% of all new cases of cancer. The precise mechanisms underlying the pathogenesis of breast cancer remain elusive, with the associated high-risk factors being challenging to manage. Consequently, developing methods for the early detection of breast cancer holds critical importance. Exosomes are nanometer-sized extracellular vesicles containing a large number of biomolecules, including lipids, carbohydrates, proteins, DNA fragments, and microRNA,<sup>2–5</sup> as exosomes in various body fluids display specific molecular profiling, and therefore tumor-derived exosomes can be considered as promising biomarkers in cancer.<sup>6,7</sup> As one of the membrane proteins on exosomes,

CD63 is known as the specific marker protein of exosomes,<sup>8</sup> and it mediates the malignancy of breast cancer through glycosylation regulation.<sup>9</sup> Therefore, detection based on CD63 membrane protein has become an important marker for breast cancer identification.

Previous research reports on exosome detection have usually focused on optimizing several traditional detection methods, such as western blotting,<sup>10</sup> nanoparticle tracking and analysis (NTA),<sup>11</sup> flow cytometry,<sup>12</sup> and enzyme-linked immunosorbent assay (ELISA).<sup>13</sup> Nonetheless, the low abundance of tumor-derived exosomes in biological fluids and the masking of their signals by heterogeneous exosomes pose significant challenges.<sup>14</sup> Additionally, traditional detection methods suffer from drawbacks such as the need for large sample volumes, low sensitivity, and the requirement for costly instruments, which hinder the flexible detection of real samples. In recent years, innovative approaches for detecting breast cancer exosomes have been developed, including fluorescence immunoassay,<sup>15</sup> surface enhanced Raman spectroscopy (SERS),<sup>16</sup> and photoelectrochemical (PEC)<sup>17</sup> and electrochemical assays.<sup>18–20</sup> Compared with spectroscopic methods,<sup>21</sup> electrochemical detection has lower background interference, higher detection sensitivity and lower cost. Compared with

<sup>a</sup> Institute of Marine Science and Technology, Shandong University, Qingdao (266000), China. E-mail: yuzhang@sdu.edu.cn

<sup>b</sup> School of Integrated Circuits, Shandong University, Jinan (250100), China



field effect transistor (FET) sensors,<sup>22</sup> electrochemical chips are simple to fabricate, and the equipment can be miniaturized for high portability. Therefore, they are prominently used in biomolecule detection.<sup>23,24</sup> Among electrochemical detection methods, electrochemical impedance spectroscopy (EIS) is a detection method that reflects biochemical processes and biorecognition events by measuring the capacitance of the electrode surface and the charge transfer resistance of the interface, which is non-destructive and has high sensitivity.<sup>25</sup>  $[\text{Fe}(\text{CN})_6]^{3-/4-}$  has been used as a redox pair for the construction of EIS biosensors in many articles in the last two years due to its redox reversibility, stable nature, high electrode compatibility, and easy preparation.<sup>26–29</sup> This method holds considerable promise in identifying breast cancer exosomes, where the choice of materials plays a pivotal role. Utilizing materials with superior electrochemical properties can significantly enhance various facets of sensing performance.

Laser-induced graphene (LIG),<sup>30</sup> produced *via* the laser-induced carbonization of polyimide (PI) films, is a foam-like carbon-based material. It is regarded as an ideal electrode material due to its straightforward processing method (no mask/reagents required), large active surface area, high cost-effectiveness, excellent biocompatibility, superior conductivity, and electrocatalytic activity. Consequently, LIG has been extensively applied in various fields, including supercapacitors,<sup>31–33</sup> triboelectric nanogenerators,<sup>34,35</sup> and a wide range of physical sensors.<sup>36–38</sup> Nonetheless, compared with early metal/covalent organic frameworks and noble metal composites, LIG suffers from problems such as low conductivity and insufficient electroactive area.<sup>39</sup> To address these issues, the addition or doping of foreign functional materials into LIG to purposefully construct suitable composite materials has emerged as an ideal solution.

Currently, there are reports of doping LIG with noble metal nanoparticles<sup>40</sup> and hydrophilic polymers.<sup>41</sup> Such modifications significantly enhance the electrochemical performance of LIG, albeit necessitating intricate and laborious preparation steps, with the modification methods often encountering stability issues. The integration of 2D/3D materials into LIG for electrochemical sensing applications has been shown to substantially improve sensor stability. Presently,  $\text{MoS}_2$  and metal–organic frameworks (MOFs) are being incorporated into LIG to fabricate temperature and gas sensors,<sup>42,43</sup> yet reports on sensors doping 2D materials with LIG for biological immunodetection remain scarce. Notable 2D materials<sup>44</sup> include graphene oxide (GO), reduced graphene oxide (rGO), and MXenes. Among these, rGO is distinguished by its superior electron transfer capabilities, attributed to the restoration of graphene's partially  $\text{sp}^2$ -hybridized carbon network. It also demonstrates commendable chemical and electrochemical stability within a certain electrochemical window, thereby enhancing the electrochemical robustness of LIG.<sup>45</sup> Furthermore, the reduction process of rGO increases the material's porosity, thus expanding its specific surface area and enhancing the

rate of biomolecule immobilization. Remarkably, rGO/LIG can be prepared in one step by  $\pi$ - $\pi$  stacking, which avoids the complicated preparation process and facilitates the improvement of the stability and sensitivity of detection.

In this study, based on the one-step doping of rGO and LIG, a stable 2D/3D structure was formed, and a biological immune sensing chip for highly sensitive detection of exosomes was constructed, achieving highly sensitive detection of exosomes. The incorporation of rGO not only enhances the hydrophobicity of the LIG surface but also creates optimal conditions for the immobilization of biomolecules, thereby improving the conductivity and stability of the sensing chip. Utilizing  $[\text{Fe}(\text{CN})_6]^{3-/4-}$  as a redox couple, the chip achieves highly sensitive detection of exosomes based on alterations in the mass transfer resistance of  $[\text{Fe}(\text{CN})_6]^{3-/4-}$  on the electrode surface, consequent to the binding of antibodies and exosomes. Furthermore, this sensing chip exhibits excellent stability, accuracy, and precision, making it suitable for the analysis of real samples. It demonstrates significant potential in differentiating between healthy individuals and breast cancer patients, highlighting its applicability in clinical diagnostics.

## Materials and methods

### Materials

PI films (200  $\mu\text{m}$  thickness) were purchased from Golden Dragon Insulation Material Co., Ltd. (Changzhou, China). Polydimethylsiloxane (PDMS) and its curing agent (Sylgard silicone elastomer kit) were obtained from Dow Corning Corporation (Midland, MI, USA). Fetal bovine serum (FBS), penicillin/streptomycin (P/S), and trypsin were sourced from Thermo Fisher Scientific Inc. (MA, USA). High-glucose Dulbecco's modified Eagle medium (DMEM) and RPMI 1640 medium were supplied by Stovovan Biopharmaceutical Co. (Logan, USA). The exosome capture antibody (Ab) was procured from Sigma-Aldrich, Inc. (St. Louis, MO, USA). Graphite powder, 30% hydrogen peroxide, polyethyleneimine (PEI), and bovine serum albumin were purchased from Macklin Biochemical Co., Ltd. (Shanghai, China). Potassium permanganate, sodium nitrate, and glutaraldehyde were obtained from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). Breast cancer serum samples were provided by Qilu Hospital of Shandong University (Jinan, China), while healthy serum samples were provided by members of our research group. All other chemicals used were of analytical grade or higher and were used without further purification. Ultrapure water ( $>18 \text{ M}\Omega \text{ cm}$ , Milli-Q) was obtained from a Millipore water purification system (Billerica, MA, USA) and used throughout the experiments.

### Apparatus

Exosomes were extracted using a CS150GXL ultracentrifuge (Hitachi, Japan). Characterization of exosomes *via* NTA was conducted using a NanoSight NS300 particle tracking analyzer (Malvern, UK). MCF-7 cells were cultured in a  $\text{CO}_2$



incubator (Panasonic, Japan). A CO<sub>2</sub> laser engraver from Kaitai (China) was utilized for laser engraving and cutting of the PI films, as well as PDMS to construct micro-nano chips. The morphology of the nanomaterials was captured using an FEI Quanta 250 FEG field emission scanning electron microscope (FEI, USA). Transmission electron microscopy (TEM) images were obtained using a Tecnai G2 F20 transmission electron microscope (FEI, USA). Raman absorption curves and Raman homogeneity mapping images of the micro-nano chip materials were acquired using a Renishaw micro laser Raman spectrometer (Renishaw, UK). The resistance of the engraved laser-induced graphene (LIG) was tested using a Keithley 2400 source meter unit (Tektronix, USA). Cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) were carried out using a CHI 660E electrochemical workstation (CH Instruments, Shanghai, China). The experiments utilized a conventional three-electrode system, comprising a laser-induced graphene electrode (diameter of 3 mm) as the working electrode, an Ag/AgCl electrode (3 M KCl) as the reference electrode, and a platinum wire as the counter electrode.

#### Cell culture and exosome extraction

MCF-7 cells were rapidly thawed in a 37 °C water bath, followed by centrifugation at 300g for 3 min to remove excess cryopreservation fluid. The cells were then cultured in DMEM medium supplemented with 10% FBS and 1% P/S antibiotics in a 5% CO<sub>2</sub> incubator. When the cell density reached approximately 80%, the culture was continued for 48 h in FBS-free medium, after which the supernatant was collected. Next, differential centrifugation was employed to separate and extract exosomes. Initially, the samples were centrifuged at 2000g for 10 min to eliminate necrotic cells, followed by further centrifugation at 1000g for 30 min to clear cell debris, yielding the supernatant. Subsequently, the supernatant was subjected to centrifugation at 100 000g and 4 °C for 70 min to acquire the exosome precipitate. The precipitate was then resuspended in DPBS buffer and centrifuged once more at 4 °C and 100 000g for 70 min to purify the exosomes. Finally, the purified exosomes were dispersed in 200 µL DPBS buffer and stored at -80 °C for future use.

#### Preparation of rGO

The preparation of rGO was based on the reduction of GO with slight modifications as reported in the literature.<sup>46</sup> Initially, ice was added to a water bath, and a stir bar was placed in a 250 mL beaker, which was then placed within the water bath. Next, 23 mL of concentrated sulfuric acid was added to the beaker followed by 1 g of graphite powder. The mixture was stirred using a magnetic stirrer for about 10 min until homogeneous. Subsequently, 0.5 g of NaNO<sub>3</sub> was added and stirred for another 10 min until evenly mixed. Thereafter, 3 g of KMnO<sub>4</sub> was added and the mixture was stirred continuously for 2 h, followed by incubation at 35 °C in a

water bath for 30 min. Next, 46 mL of deionized water was added and the temperature was raised to 80 °C, stirring for 15 min. An additional 140 mL of deionized water was added, and stirring was continued at 80 °C for 20 min. The beaker was then removed from the heat and concentrated hydrogen peroxide (30% by volume) was added until no more gas bubbles emerged, and the mixture was hot-filtered. Finally, the residue was rinsed with 20% HCl to remove excess potassium permanganate and centrifugally washed until the supernatant was neutral. The GO precipitate was obtained after freeze-drying.

For the reduction process, sodium hydroxide was added to a 10 mL GO solution (0.5 mg mL<sup>-1</sup>) to adjust the pH from approximately 4 to 10. The mixture was then incubated in a reactor at 100 °C for 6 h, followed by centrifugation at 10 000g for 10 min, and washed with clean water. The resulting rGO nanosheets were dispersed in water, sonicated, and stored at 4 °C for further use.

#### Amination of rGO

To aminate rGO, 400 µL of PEI was added to 5 mL of 0.1 mg mL<sup>-1</sup> rGO and stirred at 100g for 1 h at room temperature, followed by centrifugation at 7080g for 10 min. The precipitate was washed and subsequently re-dispersed in 5 mL of ultrapure water to obtain the PEI-rGO dispersion.

#### Construction of a bio-immunosensor chip

Initially, a complete electrode pattern was engraved using a laser engraver with optimized laser power and scanning speed settings to ensure the success of subsequent experiments. Subsequently, laser cutting technology was employed to perforate a PDMS thin layer, creating sensing microcavities with a diameter of 8 mm. The perforated PDMS layer was then precisely bonded to the engraved electrodes. Next, 5 µL of PEI-rGO dispersion was dropped onto the surface of the laser-induced graphene electrode and allowed to dry naturally at room temperature. After cleaning the electrode, 100 µL of 2.5% glutaraldehyde was added to the PEI-rGO-LIG surface and incubated for 1 h to attach antibodies. Following incubation and subsequent cleaning, 5 µL of 20 µg mL<sup>-1</sup> Ab was applied to the electrode surface and incubated for 2 h. The working electrode was then washed with PBS buffer to remove unbound antibodies, resulting in the formation of Ab-rGO-LIG. Finally, 100 µL of 3% BSA was incubated for 1 h to occupy the unmodified sites on the electrode surface, preventing non-specific adsorption. Thus, the electrochemical immunosensing chip was successfully constructed.

#### Exosome detection

Firstly, 10 µL of different concentrations of exosome solutions were added to the assembled BSA-Ab-rGO-LIG electrodes and incubated at 37 °C for 1 h to obtain exosomes-BSA-Ab-rGO-LIG complexes. Subsequently, the electrode was washed with PBS buffer to remove non-



specifically bound exosomes from the surface. Then, 100  $\mu\text{L}$  of 0.1 M KCl solution containing 5.0 mM  $[\text{Fe}(\text{CN})_6]^{3-/4-}$  (pH 7.4) was added to the sensing microcavity, with an Ag/AgCl electrode as the reference electrode and a platinum wire electrode as the counter electrode. Alternating current impedance techniques were employed for detection. The initial potential was set at 0.21 V, with a frequency range of 100 kHz to 0.1 Hz and an amplitude of 5.0 mV. The theoretical values of impedance were fitted using the Randles equivalent circuit, and the charge-transfer resistance ( $R_{ct}$ ) was used as the analysis detection signal for quantitative exosome detection.

### Detection of real samples

The serum samples from breast cancer patients provided by Qilu Hospital of Shandong University and healthy members of our laboratory team were examined. Firstly, the obtained whole blood samples were left to stand at 4  $^{\circ}\text{C}$  for 3 h, after which the light yellow serum from the top layer was collected. The acquired serum samples were then centrifuged at 3000g for 15 min to purify the serum, taking the supernatant. The purified serum was stored at  $-80^{\circ}\text{C}$  for future use. The electrochemical detection process was consistent with the extracellular vesicle extraction process used in the cell lines.

## Results and discussion


### Construction principle of the immune biosensor chip

We integrated biosensors and microelectronics to construct a biosensing chip for exosome detection. The biosensor includes a biosensing area and an electrical connection area. The detection principle of the immunobiosensing chip is depicted in Scheme 1. Firstly, PEI-rGO was introduced into the surface of LIG. The introduction of

PEI-rGO can enhance the conductivity of the electrode, and the amino group on its surface provides more sites for antibody sequestration. The observed enhancement in electrical conductivity is likely attributable to the doping interaction between LIG, a three-dimensional graphene structure, and the two-dimensional graphene rGO, forming a hybrid 2D/3D structure. This configuration not only improves the hydrophobicity of the LIG surface but also elevates its electrical conductivity, thereby enhancing the overall electrical performance of LIG and consequently increasing the sensitivity of detection. Furthermore, following the amination of rGO with PEI, antibodies are chemically bonded using glutaraldehyde as a coupling agent, which bolsters the efficiency and stability of antibody immobilization. Once immobilized, the antibodies specifically target and capture exosomes, leading to the formation of immune complexes on the electrode surface. These complexes induce changes in impedance, facilitating the highly sensitive detection of exosomes.

### Characterization of exosomes


NTA and TEM were employed to quantify and characterize the exosomes isolated from the supernatant of the human breast cancer cell line MCF-7. The results, presented in Fig. 1A, indicate a concentration of approximately  $2.24 \times 10^7$  particles per  $\mu\text{L}$  with an average diameter of 104.3 nm, demonstrating the successful extraction of a high concentration of exosomes *via* ultracentrifugation. Fig. 1B displays a TEM image of the exosomes derived from MCF-7 cells, illustrating the exosomes' characteristic cup-shaped, vesicular structure with distinct boundaries. This morphology is typical of exosomes and further validates the integrity and successful isolation of the vesicles.



**Scheme 1** Principles of bioimmunosensing microarrays, including (A) modification of biosensing interfaces and (B) exosomes detection.







**Fig. 3** CV curves of (A) LIG and (B) rGO-LIG with different scan rates in 0.1 M KCl solution containing 5 mM  $[\text{Fe}(\text{CN})_6]^{3-/4-}$ ; (C) LIG and (D) rGO-LIG peak current as a function of the square root of the scan.


and can be calculated by the Randles-Sevcik equation. The Randles-Sevcik equation<sup>47</sup> is expressed as follows:

$$I_p = 2.69 \times 10^5 A D^{1/2} n^{3/2} \nu^{1/2} c \quad (1)$$

$I_p$  represents the peak current,  $A$  represents the electroactive surface area,  $D$  represents the diffusion coefficient of  $[\text{Fe}(\text{CN})_6]^{3-/4-}$  at 25 °C, and the value of  $D$  is  $6.73 \times 10^{-6} \text{ cm}^2 \text{ s}^{-1}$ ,  $n$  represents the number of electrons transferred in the reaction,  $n$  is 1,  $\nu$  represents the scan rate,  $\nu$  is  $0.05 \text{ mV s}^{-1}$ , and  $c$  is the  $[\text{Fe}(\text{CN})_6]^{3-/4-}$  concentration. It can be calculated that the electroactive areas of LIG and rGO-LIG are  $0.182 \text{ cm}^2$  and  $0.271 \text{ cm}^2$ , respectively. From this result, it can be seen that the effective electroactive area increases significantly, which further illustrates that doping rGO further enhances the conductivity of the biosensing interface.

### Characterization of the assembly process of the immune biosensing chip

The assembly process of the immune biosensor chip was characterized using EIS and CV. As shown in Fig. 4A and B, the




**Fig. 4** (A) EIS and (B) CV curves of LIG (a), rGO-LIG (b), Ab-rGO-LIG (c), BSA-Ab-rGO-LIG (d), and exosomes-BSA-Ab-rGO-LIG (e). Here, the exosome capture concentration is  $5 \times 10^3$  particles per  $\mu\text{L}$ .


impedance spectrum of LIG shows a smaller semicircle with good reversibility of the redox peak (curve a). Due to the excellent conductivity of rGO,  $R_{ct}$  decreases after LIG is doped with rGO, and the peak current increases (curve b). After the antibody is immobilized on the electrode surface, since the antibody is a macromolecular protein and has poor conductivity,  $R_{ct}$  increases and the peak current weakens (curve c). In the same way, BSA is used to conduct the non-specific adsorption site on the electrode surface. After masking, the impedance continues to increase and the peak current decreases again (curve d). After the antibody specifically captures exosomes, an immune response complex is formed, which hinders electron transfer, and the impedance further increases, causing the peak current to further decrease (curve e). The above results show that the immune biosensing chip successfully captured and detected exosomes.

### Linearity and sensitivity

Experimental conditions were optimized and obtained as follows: antibody concentration  $20 \mu\text{g mL}^{-1}$ , Ab incubation time 120 min, exosome incubation temperature 37 °C and exosome incubation time 60 min (Fig. 5). Under the optimized experimental conditions, the analysis performance of the designed immune biosensor chip for exosomes was studied. The  $R_{ct}$  value of the sensor chip combined with different concentrations of exosomes increases with the increase in exosome concentration (Fig. 6A). The  $R_{ct}$  value and the logarithm of exosome concentration are in the range of  $5 \times 10^2$ – $5 \times 10^5$  particles per  $\mu\text{L}$ , with a good linear relationship (Fig. 6B). The expression of the linear regression equation is  $y = 653.66 \log c - 742.59$ , and the correlation coefficient  $R^2 = 0.9912$ , where  $y$  represents the impedance value  $R_{ct}$  (ohm), and  $c$  represents the exosome concentration (particles per  $\mu\text{L}$ ); based on the signal-to-noise ratio  $S/N = 3$ ,



**Fig. 5** Optimization of experimental conditions: (A) Ab concentration; (B) Ab incubation time; (C) exosome binding temperature; (D) exosome binding time.



**Fig. 6** (A) Relationship between the EIS signal and exosome concentration; (B) linear relationship between the EIS signal and logarithm of exosome concentration; (C) reproducibility of the immunobiosensor chip; (D) storage stability of the immunobiosensor chip; EIS signal (E) and statistical classification chart (F) of serum samples from breast cancer patients and healthy people.

the detection limit is calculated to be approximately 166 particles per  $\mu\text{L}$ . The introduction of rGO realizes the enhanced detection sensitivity of the sensing chip. The advantages include (1) enhancing the electrochemical signal through increasing the electrochemical surface area of the LIG electrode; (2) increasing the antibody binding ability *via* improving the hydrophobicity of the LIG surface. In Table 1, we compared the electrochemical sensors with different modified electrodes for exosome detection, and our working detection limit was lower than that of the listed sensors. In addition to using LIG as the electrode, rGO one-step modification, the electrode preparation process and its simplicity, this sensing chip has also the advantages of high portability and cost-effectiveness.

### Reproducibility, stability, and reliability of sensor chips

The signal reproducibility of the sensing chip was studied by analyzing exosomes at a concentration of  $10^5$  particles per  $\mu\text{L}$

on seven different sensing chips. Almost the same impedance signal was obtained for the seven different sensing chips, with an RSD value of only 0.98% (Fig. 6C), indicating that the constructed immune biosensor chip has good reproducibility.

The stability of the constructed immune biosensor chip was studied by detecting exosomes at a concentration of  $10^5$  particles per  $\mu\text{L}$  on five identical sensor chips two days apart for 8 days. The results are shown in Fig. 6D, where the impedance signals decreased by 1.86%, 4.39%, 6.64%, and 8.24%, respectively, compared with the initial values, and this result indicates that the prepared sensing chip has good storage stability.

The practicability and reliability of the constructed sensor chip were proved through spike recovery experiments. Under optimal experimental conditions, the constructed sensor chip was used to analyze and detect exosomes in serum samples. The exosomes with known concentrations were added to healthy human serum to perform spike recovery experiments and compare the exosome concentration assessed by the standard curve with the known amount added. As shown in Table 2, the recovery rate of the sensing chip for detecting exosome spiked samples ranged from 96.3% to 110.8%, and

**Table 1** Comparison of different modified electrodes for exosome analysis

Electrode	Modifying materials	Detection range (particles per $\mu\text{L}$ )	LOD (particles per $\mu\text{L}$ )	Ref.
GCE	PAMAM-AuNPs	$5.0 \times 10^2$ – $5.0 \times 10^5$	$2.29 \times 10^3$	48
GCE	GO-CB[7]	$4.2 \times 10^2$ – $4.2 \times 10^8$	$3.68 \times 10^2$	49
Au	AuNPs	$5.0 \times 10^2$ – $5.0 \times 10^3$	$4.82 \times 10^2$	50
Au	COFs	$1.0 \times 10^4$ – $1.0 \times 10^7$	$9.66 \times 10^3$	51
SPCE	GO-CB[7]	$1.2 \times 10^3$ – $1.2 \times 10^7$	$9.46 \times 10^2$	52
NAM	mulAu/monAu	$1.0 \times 10^3$ – $1.0 \times 10^7$	$2.80 \times 10^3$	53
LIG	rGO	$5.0 \times 10^2$ – $5.0 \times 10^5$	$1.66 \times 10^2$	This work

**Table 2** The application of the sensor chip in the analysis of serum samples ( $n = 3$ )

Sample no.	Added (particles per $\mu\text{L}$ )	Found (particles per $\mu\text{L}$ )	Recovery (%)	RSD (%)
1	$1 \times 10^3$	$1.06 \times 10^3$	106	3.68
2	$5 \times 10^3$	$4.73 \times 10^3$	94.6	8.34
3	$1 \times 10^4$	$9.63 \times 10^4$	96.3	5.59
4	$5 \times 10^4$	$5.54 \times 10^4$	110.8	9.41



the RSD ranged from 3.63% to 9.41%, indicating that the constructed sensing chip has good reliability.

### Clinical competency testing

In order to verify the clinical testing capability of the present immunobiosensing biochip, we used the constructed biochip to test the clinical serum samples, including 22 breast cancer samples and 10 healthy human samples. The results are shown in Fig. 6E, which clearly shows that the expression of exosomes in the serum of breast cancer patients is significantly higher than that in the serum of healthy people, and its  $P < 0.0001$  is derived from the statistical class analysis (Fig. 6F), which is a significant difference, thus indicating that our constructed sensing chip is able to effectively differentiate between healthy people and breast cancer patients, and it has the potential to be used for further clinical diagnosis.

### Conclusion

In summary, we developed an electrochemical immunobiosensing chip based on one-step doping of rGO with LIG to realize the quantitative detection of exosomes. The sensing chip has good stability, repeatability, precision, accuracy and reliability. Notably, the doping of the two materials formed a 2D/3D structure, which increases the electroactive area on the surface of the electrode and improves the conductivity of the electrode, and PEI-rGO, whose surface is rich in amino groups, provides more binding sites for the solidification of the antibody, thus providing a higher detection sensitivity. The sensing chip is also used for the detection of clinical samples, and it shows some potential applications in distinguishing between healthy people and breast cancer patients.

### The clinical sample ethical statement

All experiments were performed in accordance with relevant laws or guidelines and approved by the medical ethics committee of Qilu Hospital of Shandong University. Informed consent was obtained from the human participants of this study.

### Data availability

The data supporting this article have been fully included within the article.

### Author contributions

Xiaoshuang Chen: experiments, software, plotting, writing – original draft; Xiaohui Yan: investigation, experiments, formal analysis, writing – original draft; Jiaoyan Qiu: methodology, experiments, software; Xue Zhang and Yunhong Zhang: experiments; Hongpeng Zhou and Yujuan Zhao: methodology, software; Lin Han: conceptualization, supervision, writing – original draft, writing – review &

editing, project administration, validation; Yu Zhang: conceptualization, investigation, resources, methodology, visualization, funding acquisition, project administration.

### Conflicts of interest

There are no conflicts to declare.

### Acknowledgements

This work was supported by the National Key R&D Plan of China (Grant No. 2023YFB3210400), the future industries cultivate project-2022 emerging industries cultivate plan of Qingdao (22-3-4-xxgg-2-nsh), and the Collaborative Innovation Center of Technology and Equipment for Biological Diagnosis and Therapy in Universities of Shandong. We would like to thank Xiaojun Li, Haiyan Sui, Xueyun Geng and Sen Wang from Shandong University Core Facilities for Life and Environmental Sciences for their help with the TEM and SEM.

### References

- 1 H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, *Ca-Cancer J. Clin.*, 2021, **71**, 209–249.
- 2 B. N. Hannafon and W. Q. Ding, *Int. J. Mol. Sci.*, 2013, **14**, 14240–14269.
- 3 A. K. Ludwig and B. Giebel, *Int. J. Biochem. Cell Biol.*, 2012, **44**, 11–15.
- 4 J. M. Hu, Y. Sheng, K. J. Kwak, J. F. Shi, B. H. Yu and L. J. Lee, *Nat. Commun.*, 2017, **8**, 1683.
- 5 F. Raimondo, L. Morosi, C. Chinello, F. Magni and M. Pitto, *Proteomics*, 2011, **11**, 709–720.
- 6 L. Zheng, L. Zheng, B. Li, C. C. Liu and W. L. Pan, *Cancer Sci.*, 2021, **112**, 985.
- 7 Y. G. Zhou, R. M. Mohamadi, M. Poudineh, L. Kermanshah, S. Ahmed, T. S. Safaei, J. Stojcic, R. K. Nam, E. H. Sargent and S. O. Kelley, *Small*, 2016, **12**, 727–732.
- 8 M. Mathieu, N. Nevo, M. Jouve, J. I. Valenzuela, M. Maurin, F. J. Verweij, R. Palmulli, D. Lankar, F. Dingli, D. Loew, E. Rubinstein, G. Boncompain, F. Perez and C. They, *Nat. Commun.*, 2021, **12**, 4389.
- 9 Z. Song, J. Mao, R. A. Barrero, P. Wang, F. Zhang and T. Wang, *Molecules*, 2020, **25**, 5585.
- 10 E. J. K. Kowal, D. Ter-Ovanesyan, A. Regev and G. M. Church, *Extracellular Vesicles: Methods and Protocols*, 2017, vol. 1660, pp. 143–152.
- 11 C. Coughlan, K. D. Bruce, O. Burgy, T. D. Boyd, C. R. Michel, J. E. Garcia-Perez, V. Adame, P. Anton, B. M. Bettcher, H. J. Chial, M. Konigshoff, E. W. Y. Hsieh, M. Graner and H. Potter, *Curr. Protoc. Cell Biol.*, 2020, **88**, e110.
- 12 J. P. Nolan and J. C. Jones, *Platelets*, 2017, **28**, 256–262.
- 13 E. J. Goetzl, J. B. Schwartz, E. L. Abner, G. A. Jicha and D. Kapogiannis, *Ann. Neurol.*, 2018, **83**, 544–552.
- 14 H. Z. Wang, J. H. Zeng, J. Huang, H. Cheng, B. Chen, X. Hu, X. X. He, Y. Zhou and K. M. Wang, *Angew. Chem., Int. Ed.*, 2022, **61**, e202116932.



- 15 J. L. Zhang, J. J. Shi, W. Liu, K. X. Zhang, H. J. Zhao, H. L. Zhang and Z. Z. Zhang, *Sens. Actuators, B*, 2018, **276**, 552–559.
- 16 G. H. Li, N. H. Zhu, J. Zhou, K. Kang, X. X. Zhou, B. W. Ying, Q. Y. Yi and Y. Wu, *J. Mater. Chem. B*, 2021, **9**, 2709–2716.
- 17 Y. Zhao, J. Xiang, H. Cheng, X. Liu and F. Li, *Biosens. Bioelectron.*, 2021, **194**, 113581.
- 18 X. Liu, X. Gao, L. Yang, Y. Zhao and F. Li, *Anal. Chem.*, 2021, **93**, 11792–11799.
- 19 J. J. Zhang, L. Hao, Z. W. Zhao, D. C. Jiang and J. Chao, *Sens. Actuators, B*, 2022, **369**, 132332.
- 20 L. Zhang, B. Huang, J. Jin, Y. Li and N. Gu, *BMEMat*, 2024, **2**, e12057.
- 21 D. Jin, F. Yang, Y. Zhang, L. Liu, Y. Zhou, F. Wang and G. J. Zhang, *Anal. Chem.*, 2018, **90**, 14402–14411.
- 22 Y. Yu, Y. T. Li, D. Jin, F. Yang, D. Wu, M. M. Xiao, H. Zhang, Z. Y. Zhang and G. J. Zhang, *Anal. Chem.*, 2019, **91**, 10679–10686.
- 23 L. Yang, X. Yin, B. An and F. Li, *Anal. Chem.*, 2021, **93**, 1709–1716.
- 24 L. Yang, H. Guo, Q. Gao, T. Hou, J. Zhang, X. Liu and F. Li, *Anal. Chem.*, 2023, **95**, 17834–17842.
- 25 S. H. Shamsuddin, T. D. Gibson, D. C. Tomlinson, M. J. McPherson, D. G. Jayne and P. A. Millner, *Biosens. Bioelectron.*, 2021, **178**, 113013.
- 26 L. Anvari, S. M. Ghoreishi, K. Khoshnevisan, M. R. Ganjali and F. Faridbod, *J. Appl. Electrochem.*, 2023, **53**, 1843–1851.
- 27 J. Tang, J. Qin, J. J. Li, L. P. Liu and H. S. Zeng, *Biosens. Bioelectron.*, 2023, **222**, 114961.
- 28 X. Xie, D. Liu, W. L. Wang, J. Xiang, M. H. Yang and G. K. Liu, *Anal. Chem.*, 2023, **95**, 2087–2093.
- 29 G. M. Di Mari, M. Scuderi, G. S. P. Lanza, M. G. Salluzzo, M. Salemi, F. Caraci, E. Bruno, V. Strano, S. Mirabella and A. Scandurra, *Nanomaterials*, 2024, **14**, 170.
- 30 D. X. Luong, K. C. Yang, J. Yoon, S. P. Singh, T. Wang, C. J. Arnsch and J. M. Tour, *ACS Nano*, 2019, **13**, 2579–2586.
- 31 A. Lamberti, F. Clerici, M. Fontana and L. Scaltrito, *Adv. Energy Mater.*, 2016, **6**, 1600050.
- 32 W. L. Zhang, Y. J. Lei, Q. Jiang, F. W. Ming, P. Costa and H. N. Aishareef, *Small Methods*, 2019, **3**, 1900005.
- 33 L. Zhao, S. Y. Wong, J. Y. Sim, J. Zhou, X. Li and C. Wang, *BMEMat*, 2023, **1**, e12020.
- 34 M. G. Stanford, J. T. Li, Y. Chyan, Z. Wang, W. Wang and J. M. Tour, *ACS Nano*, 2019, **13**, 7166–7174.
- 35 K. H. Choi, S. Park, S. K. Hyeong, S. Bae, J. M. Hong, T. W. Kim, S. H. Lee, S. Ryu and S. K. Lee, *J. Mater. Chem. A*, 2020, **8**, 19822–19832.
- 36 A. F. Carvalho, A. J. S. Fernandes, C. Leitao, J. Deuermeier, A. C. Marques, R. Martins, E. Fortunato and F. M. Costa, *Adv. Funct. Mater.*, 2018, **28**, 1805271.
- 37 B. Kulyk, B. F. R. Silva, A. F. Carvalho, S. Silvestre, A. J. S. Fernandes, R. Martins, E. Fortunato and F. M. Costa, *ACS Appl. Mater. Interfaces*, 2021, **13**, 10210–10221.
- 38 Y. Chen, Y. Y. Zhang, F. Song, H. Y. Zhang, Q. K. Zhang, J. Xu, H. P. Wang and F. Y. Ke, *Adv. Mater. Technol.*, 2021, **6**, 2100421.
- 39 H. Lv, L. Z. Sun, X. Chen, D. D. Xu and B. Liu, *Green Chem.*, 2019, **21**, 2043–2051.
- 40 X. Hui, X. Xuan, J. Kim and J. Y. Park, *Electrochim. Acta*, 2019, **328**, 135066.
- 41 Z. B. Wang, Y. G. Wu, B. Zhu, Q. X. Chen, Y. Zhang, Z. J. Xu, D. H. Sun, L. W. Lin and D. Z. Wu, *ACS Appl. Mater. Interfaces*, 2023, **15**, 4713–4723.
- 42 W. H. Yan, W. R. Yan, T. D. Chen, J. G. Xu, Q. Tian and D. Ho, *ACS Appl. Nano Mater.*, 2020, **3**, 2545–2553.
- 43 H. Lim, H. Kwon, H. Kang, J. E. Jang and H. J. Kwon, *Nat. Commun.*, 2023, **14**, 3114.
- 44 D. Akinwande, C. J. Brennan, J. S. Bunch, P. Egberts, J. R. Felts, H. J. Gao, R. Huang, J. S. Kim, T. Li, Y. Li, K. M. Liechti, N. S. Lu, H. S. Park, E. J. Reed, P. Wang, B. I. Yakobson, T. Zhang, Y. W. Zhang, Y. Zhou and Y. Zhu, *Extreme Mech. Lett.*, 2017, **13**, 42–77.
- 45 J. N. Tiwari, V. Vijj, K. C. Kemp and K. S. Kim, *ACS Nano*, 2016, **10**, 46–80.
- 46 M. Wang, Y. J. Chu, L. Qiang, Y. K. Han, Y. Zhang and L. Han, *Sens. Diagn.*, 2022, **1**, 262–269.
- 47 T. R. L. C. Paixão, Measuring Electrochemical Surface Area of Nanomaterials versus the Randles-Sevcik Equation, *ChemElectroChem*, 2020, **7**(16), 3414–3415.
- 48 H. Zhang, Z. Wang, F. Wang, Y. Zhang, H. Wang and Y. Liu, *Talanta*, 2021, **224**, 121879.
- 49 Y. An, R. Li, F. Zhang and P. He, *Talanta*, 2021, **235**, 122790.
- 50 Q. Liu, X. Yue, Y. Li, F. Wu, M. Meng, Y. Yin and R. Xi, *Talanta*, 2021, **232**, 122451.
- 51 J. Lu, M. Wang, Y. Han, Y. Deng, Y. Zeng, C. Li, J. Yang and G. Li, *Anal. Chem.*, 2022, **94**, 5055–5061.
- 52 Y. An, R. Li, F. Zhang and P. He, *Anal. Chem.*, 2020, **92**, 5404–5410.
- 53 Y. Wang and H. Zhang, *Sens. Actuators, B*, 2023, **393**, 134294.

